Based primarily on DNA methylation analysis, medulloblastoma is known to be a heterogeneous disease comprising four distinct molecular subgroups (WNT, SHH, G3, and G4) with significant differences in their clinical and pathologic characteristics, genetic drivers of disease development and progression patterns, and clinical prognosis [18,46,47,48]. The gene discussed is SHH; the disease is medulloblastoma.